Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Net Margin (2023 - 2025)

Historic Net Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 20691.09%.

  • NewAmsterdam Pharma's Net Margin fell 206339100.0% to 20691.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 627.28%, marking a year-over-year decrease of 352400.0%. This contributed to the annual value of 530.25% for FY2024, which is 7255100.0% up from last year.
  • NewAmsterdam Pharma's Net Margin amounted to 20691.09% in Q3 2025, which was down 206339100.0% from 90.7% recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Net Margin registered a high of 57.18% during Q3 2024, and its lowest value of 20691.09% during Q3 2025.
  • For the 3-year period, NewAmsterdam Pharma's Net Margin averaged around 3954.24%, with its median value being 1464.96% (2023).
  • Its Net Margin has fluctuated over the past 5 years, first soared by 54386900bps in 2024, then crashed by -206339100bps in 2025.
  • NewAmsterdam Pharma's Net Margin (Quarter) stood at 6160.4% in 2023, then surged by 88bps to 721.71% in 2024, then plummeted by -2767bps to 20691.09% in 2025.
  • Its Net Margin was 20691.09% in Q3 2025, compared to 90.7% in Q2 2025 and 1327.3% in Q1 2025.